Johann Y. Lin, Ph.D., has extensive experience in the area of intellectual property law with a particular focus on U.S. and international patent prosecution in the areas of biotechnology, pharmaceuticals, chemistry, and diagnostic/therapeutic medical devices. In addition, he has experience in matters directed to pharmaceutical life cycle management and Hatch-Waxman patent term extensions, non-infringement, invalidity, and freedom-to-operate issues, as well as experience in intellectual property due diligence analysis associated with mergers/acquisitions, private and public financings, and initial public offerings. Dr. Lin also provides scientific and technical knowledge in connection with intellectual property litigation and has worked on patent infringement and trade secret lawsuits involving antibodies, diagnostic assays, and generic pharmaceutical products. He has prepared claim construction analyses for Markman Hearings and worked with witnesses to prepare declarations and expert reports.

Dr. Lin's legal and scientific background spans both academia and the biopharmaceutical industry. He received his advance training in radiation oncology at the Dana Farber Cancer Institute, Harvard Medical School and was awarded the Ruth Kirstein Fellowship from the National Institute of Health. He was appointed as a NIH postdoctoral research fellow at the Scripps Research Institute in La Jolla, California, where he developed functional genomic approaches to identify novel drug targets for structure-based drug design in collaboration with the Howard Hughes Medical Institute at Stanford Medical School and later with a biopharmaceutical startup company. Dr. Lin is the author of numerous scientific publications and has given a number of presentations both in the U.S. and internationally. He has an extensive network of scientific scholar, professional and entrepreneur contacts in the life sciences industry both in the U.S. and across the Pacific rim.

Dr. Lin is a graduate of Colorado State University (Ph.D., Radiation Biology with Certification in Cellular and Molecular Biology Interdisciplinary Program) and the University of California, Irvine (B.S., Chemistry and B.S., Biology).

Representative Technologies

  • Biotechnology
  • Pharmaceuticals and small molecule therapeutics, including chemical entities, dosage forms, and manufacturing processes
  • Manufacturing and fermentation technologies for recombinant antibodies and proteins
  • Organic synthesis and manufacturing methods, including click chemistry
  • Nanotube synthesis and nanotechnology for anti-infectives
  • Diagnostic / therapeutic medical devices and imaging systems
  • High throughput (HTS) screening and mass spectroscopy
  • Antibodies and immunotherapeutics, including phage display
  • Stem cell technologies, including neuroregenerative methods and treatment
  • Therapeutic / treatment methodologies
  • Regenerative medicine and wound healing technologies
  • Vaccine development, including influenza
  • Drug discovery and screening technologies, including structure-based drug design and 3D in silico screening
  • Life science reagents and kits
  • Cell signaling and cell adhesion, including integrin signaling

Selected Publications

  • Co-author, "Physical Mapping of Genes in Somatic Cell Radiation Hybrids by Comparative Genomic Hybridization to cDNA Microarrays," Genome Biology, 3(6): 0026.1-0026.7, 2002
  • Co-author, "Regional Gene Mapping Using Mixed-Radiation Hybrids and Reverse Chromosome Painting," Radiation Research 148(5), 405-412, 1997
  • Co-author, "An Ionizing Radiation-Sensitive CHO Mutant Cell Line: irs-20. IV. Genetic Complementation, V(D)J Recombination, and the SCID Phenotype," Radiation Research. 147(2), 166-171, 1997
  • Co-author, "Murine Hematopoietic Ablation by Alpha-Particle-Emitting Radiopharmaceuticals - A Potential Preparative Regimen for Bone-Marrow Transplantation," International Journal of Oncology. 2, 711-715, 1993
  • Co-author, "Cellular Kinetics, Dosimetry, and Radiobiology of Alpha-particle Radioimmunotherapy: Induction of Apoptosis," Radiation Research 130, 220-226, 1992

Selected Speaking Engagements

  • Presenter, "The Role of IP and Emerging Biotechnology Model," Academia Sinica, Taiwan, November 2013
  • Presenter, "Is There Life After Prometheus?", IP Academy Seminar, Singapore, August 17, 2012
  • Presenter, "Strategic IP Considerations in the Evolving Biotechnology landscape," Europe Asia Patent and Patent Information Conference, Singapore, 2011
  • Presenter, "Intellectual Property and Good Laboratory Practice," Chinese Academy of Science, 2010
  • Co-presenter, "A Novel Somatic-Cell Genetic Approach for Gene Mapping/Positional Cloning of an Integrin Regulatory Gene by Radiation Hybrids and Reverse Chromosome Painting," Gordon Research Conference in Molecular Cytogenetics, The Queens College, Oxford University, 2000
  • Co-presenter, "Physical Mapping and Positional Cloning of a Gene Whose Mutation May Be Responsible for the Defect in Glansmann Thrombasthenia," Jackson Laboratory Workshop on Genetics of Complex Diseases, 1998
  • Co-presenter, "The Defect Leading to Gamma-Ray Hypersensitivity in CHO Irs-20 Cells Is Similar to the SCID Defect," 10th International Congress of Radiation Research, Wurzburg, Germany, 1995
  • Co-presenter, "A Gene on Human Chromosome 8 Corrects the Defect Leading to X- or Gamma-Ray Hypersensitivity in CHO irs-20 Cell," 43rd Radiation Research Society Meeting, San Jose, California, 1995
  • Co-presenter, "Reverse-Deletion Mapping by Gamma-Ray Zapping," 42nd Radiation Research Society meeting, Nashville, Tennessee, 1994
  • Co-presenter, "Factors Influencing Radiobiologic Efficacy of Alpha-Particle-Emitting Radioimmunoconjugates," 38th Radiation Research Society meeting, New Orleans, Louisiana, 1990

Representative Matters

  • Member of a team that represented Quest Diagnostics in the sale of a stream of royalty revenue from commercialization of the drug candidate Ibrutinib to Royalty Pharma for $485 million in cash.
  • Represented a U.S. in vitro diagnostic (IVD) company in the development and implementation of a world-wide patent portfolio. The company was acquired for U.S. $355 million.
  • Member of a team that advised a U.S. Fortune 50 IVD company on intellectual property due diligence matters in connection with definitive merger agreement valued at U.S. $760 million.
  • Represents a U.S. biotechnology company in the management and development of a world-wide patent portfolio related to reagents for programmable stem cells. Advised client in connection with IP due diligence in connection with U.S. $10 million Series-A financing round.
  • Represents a U.S. biotechnology company in the development and implementation of a world-wide patent portfolio related to wound healing therapeutics. Advised client in connection with IP due diligence in connection with U.S. $20 million Series-A financing round and a U.S. $15 million Series-B financing round.
  • Represented a Healthcare private equity fund based in the Middle East in connection with the IP due diligence in connection with the financing of a U.S. medical device company specializing in bioresorbable stents for U.S. $5 million.
  • Advised and completed IP due diligence on behalf of a private equity fund based in Singapore in connection with a series-C financing of a U.S. medical device company specializing in the treatment of lung diseases for U.S. $10 million.
  • Advised a Swiss pharmaceutical company on the implementation of biosimilar IP strategy in connection with therapeutic antibodies.

Admissions

  • U.S. Patent and Trademark Office

Professional Activities

  • San Diego Intellectual Property Law Association
  • American Association for the Advancement of Science
  • BIOCOM/San Diego
  • Radiation Research Society
  • American Society of Cell Biology
  • Sino-Chinese American Biotechnology and Pharmaceutical Professional Association (SABPA)
  • American Chemical Society